Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (...
R. la Joie, M. Lin, Y. Wang et al.· medRxiv· 0 citations
A framework combining multimodal foundation model architectures (imaging, tabular, vision-language) with ARIA-specific design choices, including prediction heads separating ARIA-E and ARIA-H, severity grading, time-to-event modeling, and APOE-stratified monitoring decisions are proposed, validated through real-world ho...
Jin-Chi Wei, Evan Bloch, Michael Romano et al.· npj Dementia· 0 citations
Antemortem prediction of dementia-causing neurodegenerative disease is challenging, in part due to the frequency of co-occurring diseases. Etiologic diagnosis may be aided by the identification of highly specific clinical features or available biomarkers. Here we present an educational case of an individual with a prim...
D. L. Fischer, M. Sanderson-Cimino, W. Seeley et al.· Cognitive and Behavioral Neu...· 0 citations
Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...
R. Saloner, L. Cornelis, Joshua Downer et al.· bioRxiv· 0 citations
ASL‐derived IF‐perfusion is reduced in AD and may represent a promising imaging marker of altered CSF‐adjacent water transport physiology and further validation against established biomarkers of CSF dynamics and clearance pathways is warranted.
Mona Asghariahmadabad, P. Metanat, Michael Thomas et al.· Annals of Clinical and Trans...· 0 citations
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...
H. Oh, J. Downer, Connor D. Dietz et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.